252 related articles for article (PubMed ID: 25796163)
1. The characteristics of acromegalic patients with hyperprolactinemia and the differences with hyperprolactinemia patients.
Huan C; Cui G; Ren Z
Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):713-8. PubMed ID: 25796163
[TBL] [Abstract][Full Text] [Related]
2. Role of Ki-67 in acromegalic patients with hyperprolactinemia: retrospective analysis in 61 Chinese Patients.
Huan C; Cui G; Lu C; Qu X; Han T
Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):719-23. PubMed ID: 25796164
[TBL] [Abstract][Full Text] [Related]
3. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases.
Wang M; Mou C; Jiang M; Han L; Fan S; Huan C; Qu X; Han T; Qu Y; Xu G
Eur J Endocrinol; 2012 May; 166(5):797-802. PubMed ID: 22334636
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.
Vilar L; Naves LA; Freitas MC; Lima M; Canadas V; Albuquerque JL; Lyra R; Azevedo MF; Casulari LA
Minerva Endocrinol; 2007 Jun; 32(2):79-86. PubMed ID: 17557033
[TBL] [Abstract][Full Text] [Related]
7. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome.
Losa M; Mortini P; Barzaghi R; Gioia L; Giovanelli M
J Clin Endocrinol Metab; 2002 Jul; 87(7):3180-6. PubMed ID: 12107221
[TBL] [Abstract][Full Text] [Related]
8. [Diabetic ketoacidosis as the first manifestation of a mixed growth hormone and prolactin-secreting tumor].
Carrasco de la Fuente M; González-Albarrán O; Pérez López G; Cano Megías M
Endocrinol Nutr; 2010 Dec; 57(10):507-9. PubMed ID: 20705526
[No Abstract] [Full Text] [Related]
9. A retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin.
De Marinis L; Zuppi P; Valle D; Mancini A; Bianchi A; Lauriola L; Pasquini P; Anile C; Maira G; Giustina A
Horm Metab Res; 2002 Mar; 34(3):137-43. PubMed ID: 11972303
[TBL] [Abstract][Full Text] [Related]
10. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584
[TBL] [Abstract][Full Text] [Related]
11. Hyperprolactinemia in children: clinical features and long-term results.
Catli G; Abaci A; Altincik A; Demir K; Can S; Buyukgebiz A; Bober E
J Pediatr Endocrinol Metab; 2012; 25(11-12):1123-8. PubMed ID: 23329759
[TBL] [Abstract][Full Text] [Related]
12. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
Hong JW; Lee MK; Kim SH; Lee EJ
Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
[TBL] [Abstract][Full Text] [Related]
13. The detection of macroprolactin by precipitation and ultrafiltration methods.
Beda-Maluga K; Pisarek H; Komorowski J; Pawlikowski M; Świętosławski J; Winczyk K
Endokrynol Pol; 2011; 62(6):529-36. PubMed ID: 22144220
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of glycoprotein hormone alpha subunit in somatoprolactinic and pure somatotroph adenomas.
Vantyghem MC; Cortet C; Bauters C; Gevaert MH; Dewailly D; Lefebvre J; Mazzucca M
J Endocrinol Invest; 1998; 21(7):434-40. PubMed ID: 9766257
[TBL] [Abstract][Full Text] [Related]
15. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
16. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
Kim EH; Oh MC; Lee EJ; Kim SH
Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
[TBL] [Abstract][Full Text] [Related]
17. [Acromegaly screening in patients with hyperprolactinemia and pituitary adenoma].
Ukhanova YA; Ilovayskaya IA
Probl Endokrinol (Mosk); 2023 Sep; 70(2):4-10. PubMed ID: 38796756
[TBL] [Abstract][Full Text] [Related]
18. Acromegaly in an infant.
Blumberg DL; Sklar CA; David R; Rothenberg S; Bell J
Pediatrics; 1989 Jun; 83(6):998-1002. PubMed ID: 2657629
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia.
Le Moli R; Endert E; Fliers E; Prummel MF; Wiersinga WM
Neth J Med; 2003 Feb; 61(2):44-8. PubMed ID: 12735420
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
